Thursday September 15

Print this page

  08.00     Welcome address, Natzi Sakalihasan
    Distinguished lecture, Frank Lederle
 |  Genetics of aortic diseases
    Greg Jones, Matthew Bown





Extra-aortic cardiovascular features in Marfan syndrome - Relevance and management, Julie De Backer PDF Presentation





Whole blood DNA methylation analysis in AAA; an epigenome-wide association study, Greg Jones





Combining Mendelian genetics and genetic epidemiology for AAA, Juliette Albuisson PDF Presentation





New Insights on genetic aspect of aortic disease,  John Elefteriades PDF Presentation





Does sex matter in aortic aneurysm and dissection? Bart Loeys PDF Presentation





Genetic risk profile: insights from family based AAA NGS analysis, Danielle Majoor & Arne S Ijpma

 09.26  Discussion
    Short communications from selected papers
 09.35  • High heritability of abdominal aortic aneurysms – a population-based twinstudy,
Trine Maria Mejnert Joergensen
PDF Presentation
 09.40  • Global and gene specific DNA methylation is associated with Abdominal Aortic Aneurysms, Bradley Toghill PDF Presentation
 09.45  • End-stage human aneurysm disease in different arterial positions is similar – neurysm induction in mouse models however not, Albert Busch
 09.50  Phenotypic switching of SMCs is a potential therapeutic target in popliteal aneurysms, Albert Busch
 09.55  • Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model, Vivian de Waard PDF Presentation
  Coffee break
   |  Epidemiology and treatment of AAA
    Frank Lederle, Anders Wanhainen
  10.30  Findings from the Swedish AAA screening program, Anders Wanhainen PDF Presentation
  Is risk-factor targeted AAA screening the future? Data from the Oxford Vascular Study, Dominic Howard PDF Presentation
  Morphology of ruptured vs unruptured AAA, Janet T. Powell
  AAA rupture in Stockholm, Rebecka Hultgren PDF Presentation
  Australian trials to identify treatments to slow AAA growth, Jonathan Golledge
  AAA measurement and enlargement, Frank Lederle PDF Presentation
  CT-overestimation of AAA size severely impacts the cost-effectiveness of AAA repair, Jan Lindeman
    Short communications from selected papers
 12.10  Immunopathology in patients with AAA, Miroslav Prucha
 12.15  How does it feel to have an abdominal aortic aneurysm – a patient-centered view, Stephanie Tomee
 12.20  Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women,
Pinar Ulug
PDF Presentation
 12.25  Diameter growth rate and future indication for surgery can be predicted with inite element analysis and semi-automatic diameter measurements in small bdominal aortic aneurysms, Moritz Lindquist Liljeqvist
 12.30  Lunch break
 |  New advances in physiopathology of aortic diseases
    Audrey Courtois, Florence Pinet
 13.30  Inward neo-angiogenesis in aortic diseases, Jean-Baptiste Michel
 13.38  NETosis is associated with abdominal aortic aneurysm rupture, Sean English PDF Presentation
 13.46  The translational story of the relationship between reversible pulmonary obstructive disease and AAA, Jes Lindholt PDF Presentation
 13.54  Non-coding RNA and aneurysm, clinical implications: form experimental animal models to therapeutics approaches, Lars Maegdefessel PDF Presentation
 14.02  Cell-specific expression of non coding RNA in human AAA: new approach to find biomarkers, Florence Pinet
 14.10  Circulating miRNA associated with unstable abdominal aortic aneurysm PET positive, Audrey Courtois PDF Presentation
 14.18  Circulating vascular basement fragments are associated with the diameter of abdominal aorta, Anders Wanhainen PDF Presentation
 14.26  Discussion
    Short communications from selected papers
 14.50  • Transdifferentiation of human dermal fibroblasts to smooth muscle like cells:  novel method to study the effect of MYH11 and ACTA2 variants in the aortic neurysm wall, Natalija Bogunovic PDF Presentation
 14.55  • Live human arterial tissue slices for bench top research on pathophysiology of
aortic aneurysms; up to 90 days ex vivo preservation, Jorn Meekel
  |  Generalities on medical treatment of AAA
    Gilbert R. Upchurch, Paul Norman
 15.00  Where and why does thrombus develop in aortic disease, Barry Doyle PDF Presentation
 15.18  Focal adhesion Kinase is a novel target for pharmacotherapy of abdominal aortic aneurysm, Koichi Yoshimura
 15.26  Inhibition of aneurysmal progression by local PGG infusion in experimental porcine AAA, Jes Lindholt PDF Presentation
 15.34  TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomized controlled trial, Jonathan Golledge PDF Presentation
 15.42  What is the role of the KLF4 during the development of abdominal aortic aneurysm, Morgan Salmon PDF Presentation
 15.50  The effect of metformin on AAA, Ronald Dalman
 15.58  What do we know about AAA and diabetes and does it matter? Paul Norman PDF Presentation
 16.06  Keynote lecture. Medical treatment of the AAA in human. Fiction or reality? Gilbert R. Upchurch PDF Presentation
 16.14  Discussion 
    Short communications from selected papers
 16.30  • Inhibition of pathological vascular smooth muscle cell remodelling as a treatment strategy for abdominal aortic aneurysm, Marc Bailey
 16.35  • Canonical TGFß-signaling is triggered by inflammtion in human non-syndromic neurysm disease, but is not reflected by inducible AAA mouse models, Albert Busch
 16.40  • Phenotyping of transgenic pigs to determine the suitability of xenografts in the
treatment of aortic diseases, Ewa Strauss
PDF Presentation
 16.45  Coffee break
  |  Causes and management of ruptured AAA
    Rebecka Hultgren, Ronald Dalman
 17.15  The biology of AAA progression and rupture: beyond MMPs and inflammation, Jan Lindeman PDF Presentation
 17.23  Imaging alternatives in order to prevent rupture (volume vs diameter), Christian Gasser PDF Presentation
 17.31  Is the risk different for female or male FDRs to AAA patients? Rebecka Hultgren PDF Presentation
 17.39   Emergency EVAR – the new standard for almost every patient with a ruptured AAA (technique and own clinical data over 10 years, literature review), Hans-Henning Eckstein PDF Presentation
 17.47  Open repair of RAAA is always possible - is it always better? Lazar Davidovic PDF Presentation
 17.55  Prolonged or renewed ICU stay after AAA-repair - a “crash investigation”, Anders Wanhainen PDF Presentation

TAVI, MAVI, TEVAR, EVAR - The end of standard cardiovascular surgery?
Perspectives of a cardiac surgeon, Daniel Fink
PDF Presentation

 18.11  Staged hybrid repair of extensive TAAA, Gilbert R. Upchurch PDF Presentation
 18.19  Keynote lecture. Lessons learned from IMPROVE trial, Janet T. Powell PDF Presentation
 18.27  Questions to experts & panel discussion
    Short communications from selected papers
 18.40  • Management of visceral artery aneurysms: a 20-year single centre experience, Gianfranco Filippone PDF Presentation
 18.45  • Aortic size index could improve surveillance of women and men with AAA, Rebecka Hultgren PDF Presentation
 18.50  • How common is the classic triad of symptoms in patients with ruptured AAA? Rebecka Hultgren PDF Presentation
 18.55  • Survival disparity following AAA repair highlights inequality in socioeconomic status, Manar Khashram PDF Presentation
 19.00  • Patient reported quality and functional life after AAA repair, Manar Khashram
 19.05  End of the sessions
 20.00  Official dinner (upon registration)